Orion Oyj - Director's Dealing 2025

Orion Corporation: Managers' transactions - Satu Ahomäki

ORION CORPORATION

MANAGERS’ TRANSACTIONS

4 August 2025 at 16:10 EEST

Orion Corporation: Managers’ transactions – Satu Ahomäki

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Orion Oyj - Managers' Transactions

____________________________________________

Person subject to the notification requirement

Name: Satu Ahomäki

Position: Other senior manager

Issuer: Orion Oyj

LEI: 74370029VAHCXDR7B745

Notification type: INITIAL NOTIFICATION

Reference number: 116614/10/19

____________________________________________

Transaction date: 2025-08-04

Venue: NASDAQ HELSINKI LTD (XHEL)

Instrument type: SHARE

ISIN: FI0009014377

Nature of transaction: DISPOSAL

Transaction details

(1): Volume: 605 Unit price: 70.7 EUR

(2): Volume: 1600 Unit price: 70.7 EUR

Aggregated transactions (2):

Volume: 2205 Volume weighted average price: 70.7 EUR

____________________________________________

Transaction date: 2025-08-04

Venue: CEUX

Instrument type: SHARE

ISIN: FI0009014377

Nature of transaction: DISPOSAL

Transaction details

(1): Volume: 71 Unit price: 70.7 EUR

(2): Volume: 724 Unit price: 70.7 EUR

Aggregated transactions (2):

Volume: 795 Volume weighted average price: 70.7 EUR

Orion Corporation


Liisa Hurme President and CEO		Mikko Kemppainen General Counsel

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo, Finland

http://www.orionpharma.com

Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq Helsinki.